These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR; Feuerstein GZ Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017 [TBL] [Abstract][Full Text] [Related]
6. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Fowler MB Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708 [TBL] [Abstract][Full Text] [Related]
8. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. Bakris G J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898 [TBL] [Abstract][Full Text] [Related]
10. Carvedilol: the new role of beta blockers in congestive heart failure. Vanderhoff BT; Ruppel HM; Amsterdam PB Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960 [TBL] [Abstract][Full Text] [Related]
11. Carvedilol for heart failure: renewed interest in beta blockers. Young JB Cleve Clin J Med; 1997 Sep; 64(8):415-22. PubMed ID: 9308217 [TBL] [Abstract][Full Text] [Related]
12. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study. Ramaswamy K Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719 [TBL] [Abstract][Full Text] [Related]
13. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure. Feuerstein G; Ruffolo RR Adv Pharmacol; 1998; 42():611-5. PubMed ID: 9327976 [No Abstract] [Full Text] [Related]
14. Carvedilol: use in chronic heart failure. Doughty RN; White HD Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454 [TBL] [Abstract][Full Text] [Related]
15. Vasodilating versus first-generation β-blockers for cardiovascular protection. Fares H; Lavie CJ; Ventura HO Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211 [TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). Cleland JG; Charlesworth A; Lubsen J; Swedberg K; Remme WJ; Erhardt L; Di Lenarda A; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson PA; J Am Coll Cardiol; 2006 Apr; 47(8):1603-11. PubMed ID: 16630997 [TBL] [Abstract][Full Text] [Related]
17. Beta-blockers in heart failure: how far have we progressed? Adams KF Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):7-15. PubMed ID: 19667603 [TBL] [Abstract][Full Text] [Related]
18. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cheng J; Kamiya K; Kodama I Cardiovasc Drug Rev; 2001; 19(2):152-71. PubMed ID: 11484068 [TBL] [Abstract][Full Text] [Related]
19. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA; Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806 [TBL] [Abstract][Full Text] [Related]
20. Influence of salt intake on the antihypertensive effect of carvedilol. Ruilope LM; Lahera V J Hypertens Suppl; 1993 Jun; 11(4):S17-9. PubMed ID: 8104238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]